MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

Home・Akcijų sąrašas・Talphera Inc.

Talphera Inc.

Atidarymo kaina

0.99 -1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.96

Max

1.03

Pagrindiniai rodikliai
By Trading Economics
Darbuotojai	13

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+198.17% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-12M 49M
Ankstesnė atidarymo kaina	1.99
Ankstesnė uždarymo kaina	0.99

Talphera Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-12 23:54; UTC

Rinkos pokalbiai

CBA Could Underperform Again in 2026 -- Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-12 23:43; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-01-12 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026-01-12 21:56; UTC

Rinkos pokalbiai

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026-01-12 20:54; UTC

Uždarbis

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026-01-12 20:48; UTC

Rinkos pokalbiai

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026-01-12 20:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026-01-12 19:39; UTC

Rinkos pokalbiai

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 19:33; UTC

Rinkos pokalbiai

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026-01-12 18:21; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026-01-12 18:20; UTC

Įsigijimai, susijungimai, perėmimai

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026-01-12 18:19; UTC

Rinkos pokalbiai

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026-01-12 18:16; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026-01-12 18:01; UTC

Įsigijimai, susijungimai, perėmimai

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026-01-12 18:00; UTC

Rinkos pokalbiai

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Akcijų palyginimas

Kainos pokytis

Talphera Inc. Prognozė

Kainos tikslas

By TipRanks

198.17% į viršų

12 mėnesių prognozė

Vidutinis 3.25 USD 198.17%

Aukščiausias 3.5 USD

Žemiausias 3 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Talphera Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Talphera Inc. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.